Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial

(2021) Graham H. Jackson et al.   PLOS MEDICINE

MRD Assessment in Multiple Myeloma: Progress and Challenges

(2021) Luca Bertamini et al.   Current Hematologic Malignancy Reports

Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma – a meta-analysis of 2,596 trial patients

(2021) Niels Weinhold et al.   HAEMATOLOGICA

Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma

(2021) Pieter Sonneveld et al.   JOURNAL OF CLINICAL ONCOLOGY

OAB-055: Gain and amplification of 1q induce transcriptome deregulation and worsen the outcome of newly diagnosed Multiple Myeloma patients

(2021) Mattia D’Agostino et al.   Clinical Lymphoma Myeloma & Leukemia

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial

(2021) Francesca Gay et al.   LANCET ONCOLOGY

A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma

(2020) Sarah Goldman‐Mazur et al.   AMERICAN JOURNAL OF HEMATOLOGY

Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial

(2020) Hartmut Goldschmidt et al.   LEUKEMIA

Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN

(2020) Peter M Voorhees et al.   BLOOD

Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents

(2020) Roberto Mina et al.   Blood Cancer Journal

Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open‐label, randomised, Phase III trial

(2020) Graham H. Jackson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing

(2020) Mattia D'Agostino et al.   CLINICAL CANCER RESEARCH

Lenalidomide before and after ASCT for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial

(2020) Graham H. Jackson et al.   HAEMATOLOGICA

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

(2020) Michele Cavo et al.   Lancet Haematology

Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma

(2020) Nadine Abdallah et al.   CLINICAL CANCER RESEARCH

Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology

(2020) Shaji K. Kumar et al.   Journal of the National Comprehensive Cancer Network

Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study

(2020) Paola Tacchetti et al.   Lancet Haematology

Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial

(2020) Rowan Kuiper et al.   Blood Advances

Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma

(2019) Aurore Perrot et al.   JOURNAL OF CLINICAL ONCOLOGY

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

(2019) Thierry Facon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

(2019) Benjamin G. Barwick et al.   Nature Communications

Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs

(2019) Vittorio Montefusco et al.   HAEMATOLOGICA

Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial

(2019) Sara Bringhen et al.   HAEMATOLOGICA

Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone

(2019) Timothy M. Schmidt et al.   Blood Cancer Journal

Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

(2019) Graham H Jackson et al.   Lancet Haematology

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)

(2018) Alessandra Larocca et al.   LEUKEMIA

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

(2018) Brian A. Walker et al.   LEUKEMIA

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

(2018) María-Victoria Mateos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

(2018) Graham H Jackson et al.   LANCET ONCOLOGY

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients

(2017) V Shah et al.   LEUKEMIA

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial

(2017) H Goldschmidt et al.   LEUKEMIA

Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma

(2017) N Tandon et al.   Blood Cancer Journal

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma

(2016) Sonja Zweegman et al.   BLOOD

Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma

(2016) Valeria Magarotto et al.   BLOOD

A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma

(2016) A Larocca et al.   LEUKEMIA

Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM

(2015) M.-V. Mateos et al.   BLOOD

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

(2015) A. Palumbo et al.   BLOOD

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

(2015) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

(2015) Francesca Gay et al.   LANCET ONCOLOGY

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma

(2015) E K Mai et al.   LEUKEMIA

Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study

(2014) S. Bringhen et al.   BLOOD

GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?

(2014) M.-V. Mateos et al.   BLOOD

Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies

(2014) S. Caltagirone et al.   HAEMATOLOGICA

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival

(2014) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Autologous Transplantation and Maintenance Therapy in Multiple Myeloma

(2014) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results

(2013) F. Gay et al.   BLOOD

Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

(2012) M.-V. Mateos et al.   BLOOD

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

(2012) L. Rosinol et al.   BLOOD

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents

(2012) S. Z. Usmani et al.   HAEMATOLOGICA

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

(2012) Pieter Sonneveld et al.   JOURNAL OF CLINICAL ONCOLOGY

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial

(2010) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients

(2010) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

(2010) Michele Cavo et al.   LANCET

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

(2010) María-Victoria Mateos et al.   LANCET ONCOLOGY

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

(2009) R Fonseca et al.   LEUKEMIA